Oral Agents for the Management of Gestational Diabetes
- 1 December 2013
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Clinical Obstetrics and Gynecology
- Vol. 56 (4), 827-836
- https://doi.org/10.1097/grf.0b013e3182a8e0a5
Abstract
In gestational diabetes (GDM), achieving euglycemia through treatment decreases the risk of adverse outcomes associated with hyperglycemia. Treatment starts with diet and nutritional counseling; however, up to 50% of women will require pharmacologic therapy to meet glucose goals. Although insulin remains the only Federal Drug Administration-approved agent to treat GDM, oral hypoglycemic agents are an attractive and increasingly common alternative. Research suggests that glyburide and metformin can each effectively manage hyperglycemia in pregnancy. This review highlights research on efficacy, safety, and advantages versus disadvantages of each. We offer management and counseling strategies for clinicians caring for patients with GDM.Keywords
This publication has 8 references indexed in Scilit:
- Contemporary management of gestational diabetesCurrent Opinion in Endocrinology, Diabetes and Obesity, 2011
- Oral Hypoglycemic Agents in PregnancyObstetrics and Gynecology Clinics of North America, 2011
- The use of oral antidiabetic medications in gestational diabetes mellitusCurrent Diabetes Reports, 2009
- Safety of Glyburide for Gestational Diabetes: A Meta-Analysis of Pregnancy OutcomesAnnals of Pharmacotherapy, 2008
- Pregnancy outcome after first-trimester exposure to metformin: a meta-analysisFertility and Sterility, 2006
- Placental transfer of rosiglitazone in the first trimester of human pregnancyFertility and Sterility, 2005
- Prospective Observational Study to Establish Predictors of Glyburide Success in Women with Gestational Diabetes MellitusJournal of Perinatology, 2004
- Use of glyburide for the treatment of gestational diabetes: the San Antonio experienceThe Journal of Maternal-Fetal & Neonatal Medicine, 2004